{'output': [['bluebird bio Inc', 'COMP', 'Announce', 'three treatments', 'PRODUCT'], ['bluebird bio Inc', 'COMP', 'Operate_In', 'Biotech', 'ORG'], ['bluebird bio Inc', 'COMP', 'Expects_To_File_For_Approval', 'treatment for transfusion-dependent beta thalassemia', 'PRODUCT'], ['bluebird bio Inc', 'COMP', 'Developing_With_Partner', 'CAR-T therapy for multiple myeloma', 'PRODUCT', 'Celgene Corp', 'COMP'], ['bluebird bio Inc', 'COMP', 'Expects_To_File_For_Approval', 'treatment for cerebral adrenoleukodystrophy', 'PRODUCT'], ['bluebird bio Inc', 'COMP', 'Developing', 'treatment for sickle cell disease', 'PRODUCT'], ['bluebird bio Inc', 'COMP', 'Looking_To_Develop', 'right pricing and reimbursement strategy', 'CONCEPT'], ['Novartis', 'COMP', 'Price', 'first CAR-T treatment', 'PRODUCT', '$475,000', 'ECON_INDICATOR'], ['Gilead Sciences', 'COMP', 'Price', 'first CAR-T treatment', 'PRODUCT', '$373,000', 'ECON_INDICATOR']]}